Abstract: Representative embodiments of the present technology include a bat having a barrel shell and a frame structure. The barrel shell may include a barrel region of the bat and part of a tapered region of the bat. The frame structure may include a first portion positioned outside the barrel shell and a second portion positioned inside the barrel shell. In some embodiments, a distal end of the frame structure is in the barrel region but is longitudinally spaced from a distal end of the barrel shell. In some embodiments, the distal end of the frame structure is longitudinally spaced from an end cap of the bat. The barrel shell may flex or pivot relative to the second portion of the frame structure. In some embodiments, the only connection between the frame structure and the barrel shell within the barrel shell may be within the tapered region.

Abstract: An electrical distribution enclosure includes an electrically insulated panel defining an access portion of the enclosure and a load portion of the enclosure; at least one electrically insulated compartment panel positioned within the access portion; and two or more compartments within the access portion, each compartment separated from an adjacent compartment by an electrically insulated compartment panel, each of the two or more compartments having a front-accessible neutral connection, at least one front-accessible phase connection and a at least rear phase connection.

Abstract: Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance.

Abstract: Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance.